These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31808253)

  • 21. Saphenous Vein Graft Intervention.
    Bharadwaj AS; Mamas MA
    Interv Cardiol Clin; 2022 Oct; 11(4):383-391. PubMed ID: 36243484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing Drug-Eluting Stents to Bare-Metal Stents for Saphenous Vein Graft Lesion PCI.
    Banerjee S; Brilakis ES
    J Invasive Cardiol; 2016 Dec; 28(12):E170-E171. PubMed ID: 27922807
    [No Abstract]   [Full Text] [Related]  

  • 23. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.
    Nauta ST; Van Mieghem NM; Magro M; Deckers JW; Simsek C; Van Geuns RJ; Van Der Giessen WJ; De Jaegere P; Regar E; Van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):912-8. PubMed ID: 21542111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up results after interventional treatment of infarct-related saphenous vein graft occlusion.
    Hoffmann R; Nitendo G; Deserno V; Adamu U; Almalla M; Blindt R; Vogt F
    Coron Artery Dis; 2010 Mar; 21(2):61-4. PubMed ID: 20124993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting or bare metal stents for the treatment of saphenous vein graft disease: a Bayesian meta-analysis.
    Paradis JM; Bélisle P; Joseph L; Bertrand OF; DeLarochellière R; Déry JP; Larose E; Rodés-Cabau J; Rinfret S
    Circ Cardiovasc Interv; 2010 Dec; 3(6):565-76. PubMed ID: 21098743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions.
    Pokala NR; Menon RV; Patel SM; Christopoulos G; Christakopoulos GE; Kotsia AP; Rangan BV; Roesle M; Abdullah S; Grodin J; Kumbhani DJ; Hastings J; Banerjee S; Brilakis ES
    Catheter Cardiovasc Interv; 2016 Jan; 87(1):34-40. PubMed ID: 26033073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-examining minimal luminal diameter relocation and quantitative coronary angiography--intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial.
    Semeraro O; Agostoni P; Verheye S; Van Langenhove G; Van den Heuvel P; Convens C; Van den Branden F; Bruining N; Vermeersch P;
    EuroIntervention; 2009 Mar; 4(5):633-40. PubMed ID: 19378685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
    J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of drug-eluting stents versus bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis.
    Mamas MA; Foley J; Nair S; Wiper A; Clarke B; El-Omar M; Fraser DG; Khattar R; Neyses L; Fath-Ordoubadi F
    J Interv Cardiol; 2011 Apr; 24(2):172-80. PubMed ID: 21281356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?
    Brilakis ES; Berger PB
    Catheter Cardiovasc Interv; 2008 Nov; 72(6):815-8. PubMed ID: 19006238
    [No Abstract]   [Full Text] [Related]  

  • 34. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial.
    Badhey N; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Addo TA; Haagen D; Abdel-Karim AR; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger PB; Banerjee S; Brilakis ES
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):263-9. PubMed ID: 20665875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Drug-Eluting Stents With Bare-Metal Stents for PCI of Saphenous Vein Graft Lesions: Systematic Review and Meta-Analysis.
    Mosleh W; Gandhi S; Elsiddig M; Schwalm JD; Farkouh ME
    J Invasive Cardiol; 2016 Dec; 28(12):E139-E169. PubMed ID: 27845875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-ST-segment elevation myocardial infarction related to vulnerable neoatheroma in bare-metal stents 2 years after percutaneous coronary intervention of a coronary saphenous vein graft.
    Roleder T; Wańha W; Smolka G; Ochała A; Wojakowski W
    JACC Cardiovasc Interv; 2014 Aug; 7(8):e95-6. PubMed ID: 25086848
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients.
    Lupi A; Navarese EP; Lazzero M; Sansa M; De Servi S; Serra A; Bongo AS; Buffon A
    Circ J; 2011; 75(2):280-9. PubMed ID: 21173499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel-eluting stents for chronically occluded saphenous vein grafts (EOS) study.
    Jim MH; Ho HH; Ko RL; Siu CW; Yiu KH; Lau CP; Chow WH
    J Interv Cardiol; 2010 Feb; 23(1):40-5. PubMed ID: 20465719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry.
    Brilakis ES; Wang TY; Rao SV; Banerjee S; Goldman S; Shunk K; Kar B; Holmes DR; Dai D; Chin CT; Harding TM; Roe MT
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1068-73. PubMed ID: 20965466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.